Findings from patient-directed survey showed that the most commonly reported respiratory adverse events included dysphonia, increased sputum production, increased cough and dyspnea.
The National Tuberculosis Controllers Association and the Centers for Disease Control and Prevention have released updated guidelines for the treatment of latent tuberculosis infection.
A short, 9-month regimen of normal dose moxifloxacin maintained good effectiveness up to 24 months after therapy cessation in patients with rifampicin-resistant tuberculosis.
Daily doses of 10 to 15 mg/kg isoniazid demonstrated similar activity against tuberculosis (TB) strains with inhA mutations as 5 mg/kg doses against drug-sensitive strains.
In patients without a contraindication, rifampicin may be the safest treatment option for latent tuberculosis (TB) infection.
Treatment with 4 months of rifampin for latent tuberculosis infection was associated with higher adherence, lower costs, and lower risk for severe hepatoxicity compared with 9 months of isoniazid.
Post-tuberculosis lung disease is common in patients with HIV-associated tuberculosis at high risk for tuberculosis-associated immune reconstitution inflammatory syndrome.
Despite having a good specificity for tuberculous pleural effusion diagnosis, genotype MTBDRplus line probe assay could not be included in most diagnostic algorithms as a result of its low sensitivity.
Reporting of all verified TB cases, countable and noncountable, to the National Tuberculosis Surveillance System is necessary for capturing the true burden of TB and providing high-quality data for TB surveillance.
Safety and efficacy of isoniazid for the prevention of tuberculosis may vary between HIV-infected pregnant and postpartum women.
